Astrana Health ASTH Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $3.18B+56.4% | $2.03B+46.7% | $1.39B+21.2% | $1.14B+47.8% | ||
| $2.84B+61.1% | $1.76B+50.5% | $1.17B+24.0% | $944.69M+58.5% | ||
| $341.53M+25.8% | $271.39M+26.3% | $214.96M+7.8% | $199.48M+12.2% | ||
| 10.7%-2.6pp | 13.3%-2.2pp | 15.5%-1.9pp | 17.4%-5.5pp | ||
| $217.26M+41.0% | $154.11M+36.9% | $112.6M+45.0% | $77.67M+25.1% | ||
| $3.1B+59.5% | $1.95B+49.4% | $1.3B+25.2% | $1.04B+53.9% | ||
| $78.53M-12.1% | $89.35M+1.0% | $88.49M-15.1% | $104.26M+6.2% | ||
| 2.5%-1.9pp | 4.4%-2.0pp | 6.4%-2.7pp | 9.1%-3.6pp | ||
| $49.93M+50.9% | $33.1M+106% | $16.1M+103% | $7.92M+46.8% | ||
| -$38.92M-356% | -$8.53M-263% | $5.22M+130% | -$17.65M+13.6% | ||
| $39.61M-52.1% | $82.71M-7.9% | $89.84M+3.7% | $86.62M— | ||
| $15.53M-49.7% | $30.89M-3.5% | $31.99M-21.7% | $40.87M+29.0% | ||
| $22.49M— | —— | $60.72M+34.4% | $45.17M-34.5% | ||
| 0.7%— | —— | 4.4%+0.4pp | 3.9%-5.0pp | ||
| $0.47— | —— | $1.29+31.6% | $0.98-35.1% | ||
| $124.28M+6.0% | $117.28M+10.4% | $106.23M-12.8% | $121.81M+5.3% | ||
| 3.9%-1.9pp | 5.8%-1.9pp | 7.7%-3.0pp | 10.6%-4.3pp | ||
| $78.53M-12.1% | $89.35M+1.0% | $88.49M-15.1% | $104.26M+6.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Astrana Health's revenue?
- Astrana Health (ASTH) generated $3.5B in revenue over the trailing twelve months, up 56.7% year over year.
- Is Astrana Health profitable?
- Astrana Health reported $30.2M in net income over the trailing twelve months, a 0.9% net margin.
- What are Astrana Health's profit margins?
- Gross margin is 10.7% and operating margin is 2.5%, with a 0.9% net margin.
- What is Astrana Health's earnings per share?
- Astrana Health's diluted EPS over the trailing twelve months is $0.62.
- Where does Astrana Health's income statement data come from?
- Every line is extracted from Astrana Health's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
